Edition:
India

Tetraphase Pharmaceuticals Inc (TTPH.OQ)

TTPH.OQ on NASDAQ Stock Exchange Global Select Market

5.85USD
1:30am IST
Change (% chg)

$-0.30 (-4.88%)
Prev Close
$6.15
Open
$6.11
Day's High
$6.28
Day's Low
$5.83
Volume
113,075
Avg. Vol
228,444
52-wk High
$9.69
52-wk Low
$3.59

Chart for

About

Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral... (more)

Overall

Beta: 2.59
Market Cap(Mil.): $396.17
Shares Outstanding(Mil.): 51.05
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Tetraphase Pharmaceuticals Q3 loss per share $0.63

* Tetraphase pharmaceuticals reports third quarter 2017 financial results and highlights recent clinical and corporate achievements

02 Nov 2017

BRIEF-Tetraphase Pharmaceuticals signs commercial supply agreement with Finorga

* Tetraphase Pharmaceuticals Inc says ‍on October 16 co and finorga sas entered into a commercial supply agreement​ - sec filing

21 Oct 2017

BRIEF-TETRAPHASE PHARMACEUTICALS APPOINTS KAM UNNINAYAR AS CFO

* TETRAPHASE PHARMACEUTICALS APPOINTS KAM UNNINAYAR AS CHIEF FINANCIAL OFFICER

16 Oct 2017

BRIEF-Tetraphase Pharmaceuticals presents clinical data from oral eravacycline development program at IDWEEK 2017​

* Tetraphase Pharmaceuticals - ‍phase 2 trial in patients with complicated urinary tract infections expected to begin in h1 2018​

04 Oct 2017

BRIEF-Tetraphase Pharmaceuticals completes enrollment of ignite3 phase 3 clinical trial of eravacycline

* Tetraphase Pharmaceuticals completes enrollment of ignite3 phase 3 clinical trial of eravacycline in complicated urinary tract infections

11 Sep 2017

BRIEF-Tetraphase announces validation of IV eravacycline MAA by European Medicines Agency

* Tetraphase Pharmaceuticals announces submission and validation of IV eravacycline marketing authorization application by European Medicines Agency

17 Aug 2017

BRIEF-Tetraphase announces pricing of public offering of common stock

* Tetraphase announces pricing of public offering of common stock

28 Jul 2017

BRIEF-Tetraphase announces proposed public offering of common stock

* Tetraphase announces proposed public offering of common stock

27 Jul 2017

BRIEF-Tetraphase announces positive top-line results from Phase 3 IGNITE4 Clinical Trial

* Tetraphase Pharmaceuticals announces positive top-line results from phase 3 IGNITE4 clinical trial in complicated intra-abdominal infections

26 Jul 2017

Tetraphase's antibiotic succeeds late-stage study, shares soar

Tetraphase Pharmaceuticals Inc said its lead experimental antibiotic for serious bacterial infections met the main goal in a late-stage study, sending its shares surging nearly 23 percent in after-market trading on Tuesday.

26 Jul 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $140.79 +0.20
Pfizer Inc. (PFE.N) $36.15 +0.41
Merck & Co., Inc. (MRK.N) $56.29 +0.72
AstraZeneca plc (AZN.L) 4,877.00 +93.00

Earnings vs. Estimates